Literature DB >> 3802077

cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.

E Reed, C L Litterst, C C Thill, S H Yuspa, M C Poirier.   

Abstract

cis-Diamminedichloroplatinum(II) (cisplatin), a potent anticancer agent, is thought to exert its cytotoxic effects through DNA damage. Using a polyclonal rabbit antisera which recognizes intrastrand bidentate deoxy(ApG)- and deoxy(GpG)-N7-diammineplatinum adducts, an enzyme-linked immunosorbent assay has been developed to quantitate this adduct in cisplatin-exposed DNA. Cisplatin-DNA adducts were measured in renal, gonadal, and tumor (sarcoma) tissues of Sprague-Dawley rats following i.v. or i.p. administration of cisplatin. When drug was administered i.v. to animals fed ad libitum adduct levels were highest in kidneys, 50% lower in s.c. sarcoma, and substantially lower in gonads. Under these experimental conditions, a large interindividual variability in adduct formation was observed in renal and tumor tissues, and adduct levels in some samples were too low to measure. Higher values among individuals were obtained using tissues of animals fasted overnight and treated i.p. Adduct levels following i.p. injections of drug were higher in kidneys and gonads of male rats than in kidneys and gonads of female rats. Analysis of tissue platinum content demonstrated higher platinum levels in kidneys of male rats than in kidneys of female rats, but the magnitude of this gender difference in total tissue platinum was not as great as that observed for adduct formation. When the influence of castration on adduct formation was investigated, adduct levels in kidneys of castrated females were higher than those in sham-operated females, but adduct levels in kidneys of the castrated male animals were not substantively different from those seen in sham-operated male controls. We conclude that the route of drug administration, diet, and hormonal status of the animal are factors that may influence cisplatin-DNA adduct formation in the rat.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3802077

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

Authors:  E Reed; R F Ozols; R Tarone; S H Yuspa; M C Poirier
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

2.  Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin.

Authors:  R Parti; W Wolf
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy.

Authors:  Anna Dzagnidze; Zaza Katsarava; Julia Makhalova; Bernd Liedert; Min-Suk Yoon; Holger Kaube; Volker Limmroth; Juergen Thomale
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

Review 5.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

6.  Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.

Authors:  A Johnsson; C Olsson; O Nygren; M Nilsson; B Seiving; E Cavallin-Stahl
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo.

Authors:  Lihua Li; Yan Wang; Jun Chen; Bi Cheng; Jiehua Hu; Yuehua Zhou; Xin Gao; Liucun Gao; Xifan Mei; Meiyan Sun; Zhuomei Zhang; Haifeng Song
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-08       Impact factor: 2.629

8.  Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

Authors:  J Ma; J Verweij; A S Planting; M de Boer-Dennert; H E van Ingen; M E van der Burg; G Stoter; J H Schellens
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

Review 9.  The multiple facets of drug resistance: one history, different approaches.

Authors:  Evandro Luís Niero; Bianca Rocha-Sales; Camila Lauand; Beatriz Araujo Cortez; Marcelo Medina de Souza; Paula Rezende-Teixeira; Marcel Shiniti Urabayashi; Adam Arai Martens; Jorge Henrique Neves; Gláucia Maria Machado-Santelli
Journal:  J Exp Clin Cancer Res       Date:  2014-04-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.